[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Views 297
Citations 0
Comment & Response
March 5, 2014

Underrepresentation of Older Adults in Cancer Trials—Reply

Author Affiliations
  • 1Center for the Study of Aging and Human Development, Duke University Medical Center, Durham, North Carolina
  • 2New Cortland Center for Transitions and Health, University of Pennsylvania School of Nursing, Philadelphia
  • 3City of Hope Comprehensive Cancer Center, Duarte, California
JAMA. 2014;311(9):966-967. doi:10.1001/jama.2013.286457

In Reply Drs Luo and Kesselheim raise some relevant concerns regarding our Viewpoint on the IOM report entitled Delivering High-Quality Cancer Care: Charting a Course for a System in Crisis.1 Luo and Kesselheim recognize and share our concern regarding the underrepresentation of older adults in clinical trials. However, they disagree with the committee’s recommendation regarding amending patent law to provide patent exclusivity extension for companies conducting clinical trials in older adults for drugs to be used in that population, and suggest some alternative strategies.

First Page Preview View Large
First page PDF preview
First page PDF preview